Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) and Teligent Inc. (NASDAQ:TLGT) compete with each other in the Biotechnology sector. We will analyze and compare their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biohaven Pharmaceutical Holding Company Ltd.	N/A	0.00	240.92M	-5.61	0.00
Teligent Inc.	65.86M	0.88	36.26M	-0.38	0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Biohaven Pharmaceutical Holding Company Ltd. and Teligent Inc.

Profitability

Table 2 shows us Biohaven Pharmaceutical Holding Company Ltd. and Teligent Inc.’s return on assets, return on equity and net margins.

	Net Margins	Return on Equity	Return on Assets
Biohaven Pharmaceutical Holding Company Ltd.	0.00%	-201%	-120.6%
Teligent Inc.	-55.06%	-70.2%	-15%

Liquidity

The current Quick Ratio of Biohaven Pharmaceutical Holding Company Ltd. is 12 while its Current Ratio is 12. Meanwhile, Teligent Inc. has a Current Ratio of 1.3 while its Quick Ratio is 0.9. Biohaven Pharmaceutical Holding Company Ltd. is better positioned to pay off its short-term and long-term debts than Teligent Inc.

Insider & Institutional Ownership

Roughly 91.4% of Biohaven Pharmaceutical Holding Company Ltd. shares are held by institutional investors while 83.4% of Teligent Inc. are owned by institutional investors. About 1.1% of Biohaven Pharmaceutical Holding Company Ltd.’s share are held by insiders. Competitively, Teligent Inc. has 0.3% of it’s share held by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Biohaven Pharmaceutical Holding Company Ltd.	3.76%	23.81%	50.91%	27.74%	45.51%	27.53%
Teligent Inc.	0%	-9.41%	-26.67%	-61.01%	-43.17%	12.41%

For the past year Biohaven Pharmaceutical Holding Company Ltd.’s stock price has bigger growth than Teligent Inc.

Summary

Teligent Inc. beats on 6 of the 9 factors Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its advanced product candidate includes rimegepant, which is intended to initiate two Phase III clinical trials for the acute treatment of migraine; and trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia. The company also develops BHV-3500 for the prevention of chronic and episodic migraine; BHV-0223 for the treatment of amyotrophic lateral sclerosis, a neurodegenerative disease that affects nerve cells in the brain and spinal cord; and BHV-5000 for the treatment of symptoms associated with Rett syndrome, such as breathing irregularities. Biohaven Pharmaceutical Holding Company Ltd. was founded in 2013 and is based in New Haven, Connecticut. Biohaven Pharmaceutical Holding Company Ltd. is a subsidiary of Portage Biotech Inc.

Teligent, Inc., a specialty generic pharmaceutical company, develops, formulates, manufactures, and markets generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. The company sells generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms. It also develops, manufactures, fills, and packages topical semi-solid and liquid products for branded and generic pharmaceutical customers, as well as for over-the-counter and cosmetic markets. The companyÂ’s products are used in various applications that range from cosmetics and cosmeceuticals to the prescription treatment of conditions, such as dermatitis, psoriasis, and eczema. In addition, it offers contract formulation and contract manufacturing services comprising formulating, testing, and/or manufacturing prescription drugs and medical devices. The company was formerly known as IGI Laboratories, Inc. and changed its name to Teligent, Inc. in October 2015. Teligent, Inc. was founded in 1977 and is based in Buena, New Jersey.